Navigation Links
Cleveland Clinic researcher finds genetic mutation in castration-resistant prostate cancer
Date:8/29/2013

AUG. 29, 2013, Cleveland:

The mutation occurs in the androgen-synthesizing enzyme 3βHSD1 in castration-resistant prostate cancer (CRPC), according to research published online today in Cell. This mutation enables the tumor to make its own supply of androgens, a hormone that fuels the growth of the prostate cancer.

Prostate cancer requires a constant supply of androgens in order to sustain itself. The current standard of care for patients with metastatic prostate cancer is medical castration, the ability to interfere with the body's production of testosterone (androgens) using medications that disrupt the process. Oftentimes, metastatic prostate cancer flourishes despite the lack of testosterone in the bloodstream, creating CRPC. These tumors are able to exist without the body's supply of testosterone by creating androgens within the tumor cell; however, increased androgen synthesis has not yet been attributable to any known mutations. The Cleveland Clinic discovery shows that the 3βHSD1 mutation makes this enzyme hyperactive to create androgens.

"This discovery gives us the ability to identify molecular subtypes of prostate cancer known to resist treatment. By finding the mutated enzyme, we can now investigate treatments that block it. This kind of strategy is the crux of personalized medicine which is currently used as the standard of care for some forms of lung cancer and melanoma," said Nima Sharifi, M.D., Kendrick Family Chair for Prostate Cancer Research at Cleveland Clinic, who led the research.

The 3βHSD1 mutation can occur within CRPC tumors and it can also come from germline DNA, which is inherited from maternal and paternal sources.

The research found that laboratory models of human prostate cancer fall into two categories of androgen synthesis: those that make androgens slowly and those that do so rapidly. Next, they found that the 3βHSD1 mutation explains the difference between these two categories and that DNA from some patient tumors also contains this mutation. The mutation works by opening the floodgates to androgen synthesis, essentially throwing fuel on the fire that promotes tumor progression.

In an era of personalized cancer care, there is increased focus on defining and treating cancer by its genetic abnormalities. Tumor-promoting enzyme mutations in several cancers have been identified and, subsequently, have led to the development of targeted drug therapies, improving outcomes for patients.

"The past decade has seen an explosion of molecularly targeted therapies that are matched to specific mutations in a given patient's tumor," says Dr. Sharifi. "However, no drug-targeting based on enzyme mutations exists for the standard treatment of metastatic CRPC. With this finding, we have the opportunity for matching a mutant disease-driving biomarker with a pharmacologic inhibitor."

Prostate cancer is the most common cancer in men, with nearly 240,000 new cases diagnosed each year in the United States. According to the American Cancer Society, there will be an estimated 30,000 deaths due to prostate cancer in 2013. Almost every man who dies of prostate cancer dies with castration-resistant prostate cancer.


'/>"/>

Contact: Stephanie Jansky
JANSKYS@ccf.org
216-363-5869
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. CE Lectures on the Dental Treatment of Snoring and Sleep Apnea Include Rochester, Cleveland and Ft. Lauderdale, as Sleep Seminar Destinations
2. Cleveland Indians vs. Detroit Tigers Tickets: Cheap Concert Tickets Slashes Prices on All Indians vs. Tigers Tickets for August 5th - August 8th Series Progressive Field
3. National Transitions of Care Coalition to Host Regional Summit in Cleveland
4. Maroon 5 & Kelly Clarkson Ticket Prices Slashed for Concerts in Long Island, Holmdel, Cincinnati, Pittsburgh, Camden/Philly, Boston/Mansfield, Chicago, Cleveland & Detroi
5. Explorys Proud to Sponsor Cleveland GiveCamp
6. NEONI Participates in Healthcare Career Event at Cleveland Convention Center Grand Opening
7. Cleveland Clinic Laboratories to provide testing and diagnostic services to ACL Laboratories
8. Book of Mormon Tickets: Prices Slashed on Book of Mormon Tickets in New York, Chicago, Cleveland, Buffalo, Washington DC, Minneapolis, Houston and San Antonio
9. Cancer Survivor David Emerson Awarded Volkswagen Cup at Cleveland Marathon
10. Nine Inch Nails Tickets (NIN) Tickets Go On Public Sale for St. Paul, Toronto, Cleveland, Detroit, Boston, Brooklyn, Newark, Washington DC, Las Vegas, Portland on June 14th
11. Justin Timberlake Tickets: Cheap Concert Tickets Announces that Justin Timberlake Tickets Go Onsale 6/3 for Concerts in Omaha, St. Paul, Fargo, Pittsburgh, Cleveland, Indianapolis and St. Louis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... Pekin, IL (PRWEB) , ... June 28, 2017 , ... ... research shows that every 62 minutes, at least one person dies as a direct ... grows, a greater need exists for qualified treatment providers. The iaedp Foundation meets this ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) ... year study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium ... brine-impacted groundwater. As a part of the study, batch adsorption experiments were conducted ...
(Date:6/27/2017)... Fla. (PRWEB) , ... June 27, 2017 , ... ... today announced the appointment of Mike Finnegan to the position of Executive Vice ... years of experience in healthcare technology, telehealth and medical device sales leadership. He ...
(Date:6/27/2017)... ... 27, 2017 , ... The Congressional Budget Office (CBO) projects that the Better ... Patient Protection and Affordable Care Act (ACA), would result in 22 million Americans losing ... law. , More than 20 million Americans have gained health insurance under the ACA, ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the development of ... R&D and Head of Virology Kristin Bedard has been invited ... and Beyond meeting sponsored by Life Science Washington.  This ... AM PDT at the Agora Conference Center in ... be joined by other leaders in infectious disease research and ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
Breaking Medicine Technology: